Nexalis Therapeutics Limited has released a press release.
Study Order Executed for Phase 2 BTcP Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Nexalis Therapeutics Limited on 6ix
In the deck
Earlier from Nexalis Therapeutics
- Updated Dec24 Quarterly Activities Report
- Dec24 Quarterly Activities Report
- Dec24 Appendix 4C Cash Flow Report
- Shareholder Update
- Issue of Securities Following General Meeting Approval
Later from Nexalis Therapeutics
- IRX-616a Study Order Executed to Commence Phase 1
- IRX Completes First Drawdown Under Clendon Facility
- Mar25 Appendix 4C Cash Flow Report
- Mar25 Quarterly Activities Report
- Jun25 Appendix 4C Cash Flow Report
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics